A5V4d

Guideline summary
Number Research recommendation See
section
Management by remote assessment
RR3 The GDG recommends that a UK study is undertaken to determine
the validity of symptoms reported on remote assessment for
children with fever. [2007]
Management by the non-paediatric practitioner
Management according to risk of serious illness 7.2
RR 4 The GDG recommends that research is carried out on referral
patterns between primary and secondary care for children with
fever, so the health economic impact of this and future guidelines
can be estimated.
Management by the paediatric specialist
Diagnosis
RR 5 The GDG recommends that a UK study of the performance
characteristics and cost-effectiveness of procalcitonin versus Creactive
protein in identifying serious bacterial infection in children
with fever without apparent source be carried out. [2007].
Antipyretics
RR 6 The GDG recommends that studies are conducted in primary care
and secondary care to determine whether examination or reexamination
after a dose of antipyretic medication is of benefit in
differentiating children with serious illness from those with other
conditions. [2007]
Advice for home care
Home-based antipyretic use
RR7 The GDG recommends studies on home-based antipyretic use
and parental perception of distress caused by fever. [new 2013].
1.10 Other versions of the guideline
This section will be completed following the stakeholder consultation.
1.11 Schedule for updating the guideline
NICE clinical guidelines are updated so that recommendations take into account important new
information. New evidence is checked after publication, and healthcare professionals and patients are
asked for their views; we use this information to decide whether all or part of a guideline needs
updating. If important new evidence is published at other times, we may decide to do a more rapid
update of some recommendations. Please see NICE website for information about updating the
guideline.
6.2
8.3
8.3
10.1
25